These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9343795)

  • 1. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients.
    Scharfstein JA; Paltiel AD; Freedberg KA
    Med Decis Making; 1997; 17(4):373-81. PubMed ID: 9343795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
    Rely K; Alexandre PK; Escudero GS
    Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection.
    Manfredi R; Mastroianni A; Coronado OV; Chiodo F
    Arch Intern Med; 1997 Jan; 157(1):64-9. PubMed ID: 8996042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.
    Freedberg KA; Hardy WD; Holzman RS; Tosteson AN; Craven DE
    Med Decis Making; 1996; 16(1):29-35. PubMed ID: 8717596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia.
    Micol R; Tajahmady A; Lortholary O; Balkan S; Quillet C; Dousset JP; Chanroeun H; Madec Y; Fontanet A; Yazdanpanah Y
    PLoS One; 2010 Nov; 5(11):e13856. PubMed ID: 21085478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
    O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
    Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis.
    Wakerly L; Craig AM; Malek M; Hoffmeyer U; Lloyd A; Valette F; Phillips R; Zabihollah M
    J Hosp Infect; 1996 May; 33(1):35-48. PubMed ID: 8738200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
    O'Sullivan AK; Weinstein MC; Pandya A; Thompson D; Langston AA; Perfect JR; Papadopoulos G
    Am J Health Syst Pharm; 2012 Jan; 69(2):149-56. PubMed ID: 22215361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
    de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
    Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy.
    Nomura K; Kawasugi K; Morimoto T
    Eur J Cancer Care (Engl); 2006 Mar; 15(1):44-50. PubMed ID: 16441676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
    Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
    Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
    J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
    Sung AH; Marcella SW; Xie Y
    J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole vs fluconazole or itraconazole for prevention of invasive fungal diseases in patients with acute myeloid leukemia or myelodysplastic syndrome: a cost-effectiveness analysis in an Asian teaching hospital.
    Chan TS; Marcella SW; Gill H; Hwang YY; Kwong YL
    J Med Econ; 2016; 19(1):77-83. PubMed ID: 26366612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
    de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
    Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
    Scharfstein JA; Paltiel AD; Weinstein MC; Seage GR; Losina E; Craven DE; Freedberg KA
    Int J Technol Assess Health Care; 1999; 15(3):531-47. PubMed ID: 10874380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.